Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGN-Ex05e in Severe, Treatment-Resistant Autism Spectrum Disorder
NCT07433517Phase 1Not yet recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of VGN-Ex05e in Autism Spectrum Disorder (ASD), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Adverse Events at 1 year. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
VGN-Ex05e
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07433517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07433517.